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Objective: Renal artery in-stent restenosis (RAISR) is not an infrequent occurrence and may be in part responsible for the
failure of renal stents to improve clinical outcome. A variety of treatments have been used to restore patency, with mixed
results. These include repeated percutaneous transluminal renal angioplasty (PTRA), repeated PTRA with bare-metal
stents, and repeated PTRA with drug-eluting stents or covered stents. Endovascular brachytherapy (EVBT) has been
proven effective in preventing recurrent neointimal hyperplasia in coronary bare-metal stents. This prompted our group
to study the effect of EVBT on RAISR.
Methods: From 2004 to 2012, 21 patients (23 renal arteries) developed RAISR#30 months after the initial procedure and
were subsequently treated with EVBT. Five patients had at least one prior PTRA for recurrent restenosis. Renal artery
duplex scanning was performed as a baseline study within a few days of the EVBT and then every 6 months. All patients
who had EVBT were concurrently treated by PTRA and EVBT on the basis of existing protocols. Patency of the treated
stents was evaluated by Kaplan-Meier survival curves.
Results: The average onset of the original RAISR was 116 9 months (range, 2-30 months; median, 8 months). The initial
technical success of combined PTRA and EVBT was 100%. Mean follow-up was 44 6 18 months (range, 14-84 months).
Of ﬁve patients who had PTRA before EVBT, four were available for long-term follow-up. These four patients had a
combined total number of ﬁve PTRAs before EVBT, with recurrent stenosis developing on average by 12 months. After
EVBT, three stents were patent at 39, 48, and 65 months, and one stent restenosed at 42 months. This was the only
patient in the entire series to develop restenosis after EVBT.
Conclusions: This retrospective experience with a relatively small number of patients undergoing concurrent EVBT/
PTRA for recurrent stenosis in stents placed to treat atherosclerotic renal artery stenosis suggests that EVBT is safe and
provides long-term freedom from recurrent stenosis. (J Vasc Surg 2014;60:1599-604.)Stenting of renal arteries revolutionized percutaneous
renal artery revascularization. Patency dramatically improved
compared with percutaneous transluminal renal angioplasty
(PTRA) alone.1
Unfortunately, renal artery in-stent restenosis (RAISR)
is not an infrequent occurrence, with medium-term recur-
rence rates ranging from 6% to 49%.2-5 Recent reviews with
longer follow-up reveal consistently higher rates of resteno-
sis. In a series of 123 stented renal arteries with follow-up
surveillance during a mean of 30 months, 57% developed
duplex ultrasound criteria for recurrent stenosis.6 In
another series of 101 renal arteries, restenosis was 27% at
an average of 5.5 months, and at 18 months, the restenosis
rate was 60%.7
A variety of treatments for RAISR have been used, but
none have proved consistently effective or superior, and
long-term data are lacking. Endovascular brachytherapy
(EVBT) has proved to be somewhat effective in preventingthe Department of Surgery, Florida State University Medical School.
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metal stent restenosis.8 There have been few reports demon-
strating the efﬁcacy of EVBT for RAISR, and most of these
involve small numbers with limited follow-up.3 Beginning
in 2004, we began to use EVBT for RAISR, and we now
report our results with this ongoing experience.
METHODS
From 2004 to 2012, 21 patients (23 renal arteries)
who developed RAISR #30 months after the initial renal
artery stenting were treated with PTRA with EVBT. The
study and the waiver of consent were speciﬁcally approved
by the Institutional Review Board of Sarasota Memorial
Hospital, where cases of brachytherapy were performed.
These patients represent not all patients treated for RAISR
at that hospital but rather a consecutive experience from
patients previously treated by or referred to one treating
vascular surgeon (S.S.).
After the initial renal artery stenting (Boston Scientiﬁc
Express SD balloon expandable stents; Boston Scientiﬁc,
Natick, Mass) and after EVBT, all patients had completion
angiography and follow-up renal duplex ultrasonography
performed in the ﬁrst week and every 6 months thereafter.
Follow-up also included analysis of antihypertensive medi-
cations, measurement of serum creatinine and blood urea
nitrogen (BUN) concentration, and blood pressure mea-
surements. The initial stent sizes were two 4-mm, 18
5-mm, and three 6-mm stents.1599
Table I. Patient demographics
Mean age 6 SD, years 80.4 6 9.2
Males 13
Females 8
Diabetes 38%
Hypertension 100%
Hyperlipidemia 71%
Smoking history 95%
Coronary artery disease 62%
Peripheral vascular disease 52%
Previous stroke 14%
No. of blood pressure drugs 1.8 6 1.2
Chronic kidney disease 24%
SD, Standard deviation.
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peak systolic velocity within the stent, waveform analysis
distal to the stent, and renal-to-aortic ratio were used as
diagnostic criteria for recurrent stenosis. RAISR (>60%
diameter) was determined by renal-to-aortic ratio of >3.5
or a peak systolic velocity of >280 cm/s. All patients
who met duplex ultrasound criteria for restenosis then un-
derwent conﬁrmatory renal angiography. Restenosis based
on renal angiography was deﬁned as greater than >75%
reduction in diameter at any point within the stent. Pres-
sure measurements were not recorded.
Baseline demographic characteristics and risk factors are
recorded in Table I. Notably, most patients were smokers,
were hypertensive, and had elevated cholesterol levels.
Procedures were performed through a standard retro-
grade femoral puncture under local anesthesia. After the
6F sheath was inserted, each patient was given a 5000-
unit intravenous heparin bolus. The 6F guide catheters
were placed in the stented artery over a 0.014-inch
Thruway wire (Boston Scientiﬁc). Intravascular ultrasound
(IVUS) examination (Galaxy2 IVUS Imaging System; Bos-
ton Scientiﬁc) was performed with a 40-MHz Atlantis
catheter rapid exchange in all patients to conﬁrm the size
of the vessel, to assist in balloon sizing, and to document
the success of the PTRA procedure diameter. IVUS
conﬁrmed the angiographic ﬁndings in all patients. After
successful balloon angioplasty of the area of RAISR, the
treatment catheter rapid exchange was advanced over a
wire to the treatment area. EVBT was then accomplished
according to the following established protocol.
EVBT was performed with 90Sr/90Y beta-emitting sys-
tem (Novoste Beta-Cath 3.5F System; Best Vascular, Nor-
cross, Ga). The actual isotope in the unit is strontium 90
(90Sr). Strontium 90 is a pure beta emitter with a half-life
of 28.8 years and 546 keV beta energy. The daughter
isotope is yttrium 90 (90Y). The yttrium 90 is used for ther-
apy because the strontium 90 is absorbed by the steel
capsule. The system, which was approved by the U.S.
Food and Drug Administration (FDA) for coronary artery
in-stent restenosis, is composed of a hand-held device
housing a 90Sr radiation source train of 40 mm and a
3.5 F delivery catheter. A treatment margin of at least
5 mm proximal and distal to the stent was included to treat
edge effect. The beta radiation system is 40 mm long, soany extra length of the catheter was positioned in the aorta
to reduce beta radiation to the healthy renal artery.
Accurate placement of the catheter was conﬁrmed by
ﬂuoroscopy using ﬁducial markers in the treatment cath-
eter. Once in place, the hand-held unit was connected to
the treatment catheter. The reference vessel diameter was
then used to calculate the treatment dwell time. Because
dose recommendations were established for coronary ves-
sels up to 4 mm, a customized dose calculation was
required when the vessels exceeded this. The goal was to
prescribe a dose to a distance of 2 mm from the catheter,
which would lead to the delivery of 18.4 Gy to the vessel
lumen. Unfortunately, there was no way to center the
treatment catheter. In the Swiss trial, a dose of 25 Gy
was used; however, the authors calculated that eccentric
centering of the catheter could result in a maximal poten-
tial dose of 44 Gy.9 Jahraus et al10 also noted that eccentric
placement of the catheter could result in overdose or
underdose areas of the arterial wall.
These same issues have been raised for coronary
brachytherapy and have been countered by the notion
that a broad range of dose may be acceptable.
Treatment commenced when the source train was veri-
ﬁed to be in position within the catheter. Following the
calculated dwell time, the source was returned to the
hand-held unit, and the treatment was complete. Typical
treatment time varied according to the size of the stent
but on average took no more than 8 minutes.
All patients were treated with aspirin (81 mg) indeﬁ-
nitely. Clopidogrel 75 mg daily was also prescribed and
continued for at least 1 year. Major complications were
deﬁned as death, secondary interventions, increase in
serum creatinine concentration ($15%), or dialysis within
30 days of treatment. Minor events were puncture site
complications, renal embolization or renal artery dissec-
tions, and contrast agent reactions.
Kaplan-Meier survival curves were constructed to assess
patency over time. Paired t-test was used to compare initial
and ﬁnal variables; continuous variables are expressed as
mean 6 standard deviation, and categorical variables are
expressed as percentages.
RESULTS
Twenty-one patients (23 renal arteries) who developed
RAISR#30 months (median, 8 months; mean, 11 months;
standard deviation 6 9) after the initial procedure were
treated from 2004 to 2012. Their mean age was 80.4 6
9.2 years (median, 82 years).
The mean time to secondary intervention was 11 6
9 months (median, 8 months; range, 2-30 months). Fifteen
patients (71.4%) required reintervention at#13 months. In
16 patients, this was the ﬁrst episode of RAISR. Five were
for recurrent restenosis. RAISR was diagnosed by renal
duplex ultrasonography in 18 patients, all of whom had
conﬁrmatory angiography. Three patients had arteriography
for other reasons and RAISR was incidentally identiﬁed.
The creatinine levels averaged 1.32 6 0.4 mg/dL
(median, 1.2 mg/dL) at the time of restenosis and were
Table II. Comparison of renal function, blood pressures,
and number of medications at the time of endovascular
brachytherapy (EVBT) compared with the values at the
most recent follow-up visit
Paired t-test
Mean
P
value
At the time
of EVBT
Most recent
follow-up
BUN, mg/dL 31 27 .21
Creatinine, mg/dL 1.32 1.44 .23
Systolic blood pressure, mm Hg 159 141 <.0001
Diastolic blood pressure, mm Hg 74 68 .16
No. of medications 1.95 2.32 .23
BUN, Blood urea nitrogen.
Fig. The Kaplan-Meier freedom from restenosis curves stratiﬁed
into the initial renal artery in-stent restenosis (RAISR) group
compared with the same RAISR group after receiving endovas-
cular brachytherapy (EVBT) (P < .0001). The standard error
reaches 10% at 6 months for the initial RAISR group but does not
reach 10% for the RAISR after EVBT group.
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follow-up after EVBT (Table II). The serum creatinine
concentration at follow-up did not differ signiﬁcantly
from the baseline value (P < .2257). The BUN concentra-
tion was 31.2 6 15.2 mg/dL (median, 26 mg/dL) at the
time of restenosis and 26.7 6 9.1 mg/dL (median,
26 mg/dL) at the latest follow-up after EVBT. The
BUN concentration at follow-up also did not differ signif-
icantly from the baseline value (P < .2082). After the
secondary intervention, at the latest follow-up, 28.6% had
an increase of the serum creatinine concentration of
>20%, 23.8% had an increase of the serum creatinine
concentration <20%, 19% had no change in the creatinine
concentration, and 29% had a decrease in the creatinine
concentration. Thus, the renal function for 15 patients
(71.4%) improved or remained stable.
All patients were successfully dilated on the basis of
visually estimated angiographic residual stenosis <20%
and IVUS residual stenosis <20%. Adjunctive renal artery
EVBT was able to be performed in all patients. There
were no major complications or minor complications.
No procedural or in-hospital adverse events or complica-
tions related to the procedure occurred or were determined
to have occurred within 30 days of the procedure.
The mean follow-up was 44 6 18 months (median,
42 months; range, 14-84 months). In the entire series,
only one patient developed restenosis that occurred at
42 months. This patient was subsequently treated with a
drug-eluting stent and EVBT but died of other causes
8 months later. The remaining 20 patients were free
from restenosis at the time of the most recent follow-up.
The mean patency for the RAISR group after EVBT was
44 months compared with the mean patency of the initial
RAISR group, which was 11 months (P < .0001) (Fig).
A subgroup of ﬁve patients had PTRA for RAISR before
the EVBT. Four of these patients were available for follow-
up. The ﬁrst patient had RAISR treated with PTRA and
developed RAISR at 23 months. After EVBT, the renal ar-
tery was free of restenosis at 65 months. The second patient
had RAISR treated with PTRA and remained free of stenosisfor only 2 months. After repeated PTRA and EVBT, the
renal artery was free from restenosis at 48 months. The third
patient had RAISR treated with PTRA and remained free of
stenosis for only 8 months, and after EVBT, the renal artery
was free of restenosis at 39 months. The fourth patient had
RAISR treated with PTRA and remained free of stenosis for
4 months. The patient had repeated PTRA again and reste-
nosed 8 months later. After EVBT, the renal artery reste-
nosed at 42 months. This patient was the only patient in
the entire series to develop recurrent RAISR after EVBT.
These four patients had a combined total number of ﬁve
PTRAs beforeEVBT,with an average patency of 11months.
After EVBT, the stents had a mean patency of 48 months.
Of the entire series, two patients had small stents placed
(4 mm), and both patients demonstrated long-term patency
after PTRA and EVBT at 34 months and 42 months.
Blood pressures at the time of EVBT and at long-term
follow-up were available in 82% of the patients (Table II).
The initial systolic blood pressure averaged 159 mm Hg; at
follow-up, it was 141 mm Hg, and this drop in systolic
blood pressure was signiﬁcant (P < .0001). The diastolic
blood pressures dropped from 74 mm Hg initially to
68 mm Hg at follow-up (P ¼ .1550). There was a slight
increase in the number of medications for hypertension,
but this was not signiﬁcant (P ¼ .2296).
Risks of side effects of endovascular radiation, including
thrombosis, edge defect, accelerated atherosclerosis, and
recurrent restenosis, which have been seen in the coronary
arteries, were not encountered in this series.11
DISCUSSION
In-stent restenosis prevalence. RAISR is a signiﬁcant
problemwith renal stents andmay account in part for the lack
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RAISR vary widely in part because of the number of factors
associated with restenosis, including small vessel size
(usually <4.5 mm), length of stented segment, smoking,
time to evaluation for restenosis, bilateral renal artery disease,
presence of diabetes, and duration of follow-up.3,13-16 In a
meta-analysis of RAISR, the overall 1-year restenosis was
17%,with awide rangeof 0% to 39%.16Thiswide variability is
further compounded by whether duplex ultrasonography or
angiography was used to deﬁne restenosis. Regardless of the
threshold used to deﬁne restenosis, the overall restenosis rate
after stenting of renal artery stenosis is substantial (6%-60%),
and irrespective of whether our criteria for deﬁning RAISR
are correct, all patients in our series were conﬁrmed by
angiography to have a >75% RAISR.2-5,7
In-stent restenosis treatment with balloon angio-
plasty. Multiple methods have been proposed to treat
RAISR, yet none have proved to be effective, with recurrent
RAISR rates of 27% and 36%.17,18 These include repeated
balloon angioplasty, cutting balloon angioplasty, stent-in-
stent angioplasty, drug-eluting stents, covered stents, and
brachytherapy.3,6,9-11,17-27 RAISR seems to be the highest
when treatment is with PTRA alone. Stone et al19 treated 27
patients with repeated PTRA for RAISR with a target vessel
revascularization rate of 23%. In another study of 15 patients
who were mostly treated with repeated PTRA alone, 25%
had angiographic evidence of restenosis by 11 months.17
Zeller et al18 treated seven patients with repeated PTRA
for RAISR, and ﬁve (71%) recurred; in that series, cutting
balloon angioplasty proved to be no better than PTRA, with
a recurrence of 100%. In our series, ﬁve patients had
repeated PTRA for RAISR (before EVBT), and all of these
recurred at an average of 11 months.
In-stent restenosis treatment with stent in stent.
Other investigators have tried placing a second stent within
the original renal stent. However, stretching of the outer
wall of the artery may further stimulate myointimal hyperpla-
sia in a patient known to be prone to neointimal proliferation,
leading to long-term failure of the stent.20 Two studies
reviewed theuseofbare-metal stents forRAISR, andbothhad
a mean follow-up of 36 months. In the smaller series of seven
patients, there was a 43% restenosis rate.18 In the larger series
of 77 patients, the target vessel revascularization was 20%.19
However, target vessel revascularization is not necessarily a
valid method of evaluating restenosis because some patients
with restenosis may not have requested or required retreat-
ment. Accordingly, in another large series of 65 patients with
RAISR, the restenosis rate was 50% at 3 years.6
In-stent restenosis treatment with drug-eluting
stents. Drug-eluting stents have signiﬁcantly reduced the
incidence of in-stent restenosis in the native coronary
arteries.28
There are emerging data that drug-eluting stent place-
ment is an effective therapy for coronary in-stent resteno-
sis.29,30 This has led to use of coronary drug-eluting
stents in RAISR. Three case reports with limited follow-
up (<12 months) do reveal mixed success with drug-
eluting stent placement for RAISR.15,21,22 Two stentswere patent at 6 and 12 months. In the third report, a pa-
tient had bilateral RAISR treated with drug-eluting stents,
and both arteries restenosed by 12 months.15 Results in
larger series of the use of drug-eluting stents to treat
RAISR have been highly variable. Zeller et al18 treated
10 patients with drug-eluting stents and found no recur-
rences at a mean follow-up of 36 months. However, in
another series, eight patients were treated with drug-
eluting stents for RAISR, and two (25%) required another
intervention; late occlusions eventually developed in three
patients (37.5%) despite antiplatelet therapy.19 Kiernan
et al23 reported on 22 renal arteries in 16 patients with
RAISR treated with drug-eluting stents with an average
follow-up of 12 months, with restenosis of 71.4%. Further,
the drug-eluting stent is more costly than the bare-metal
stent and likely will need long-term antiplatelet therapy
with aspirin and clopidogrel.31 Concerns have also been
raised about the durability of the thinner coronary stents
in the renal arteries that may lack the radial strength needed
to overcome the increased potential for elastic recoil of
aorto-ostial renal artery stenosis.22 The current use of cor-
onary drug-eluting stents in renal arteries is also limited by
the 4-mm maximum size of available stents, although the
directions for use for some of these stents (ION and Pro-
mus) state that they can be dilated to 5.75 mm.
In-stent restenosis treatment with covered stents.
RAISR has been shown to respond to covered stents with
some success. A patient with bilateral RAISR was treated
with drug-eluting stents, and both arteries restenosed at
12 months.15 The patient was then treated with covered
stents, and at 12 months the right side was patent but the
left was 50% restenosed. In a small series, covered stents
offered lower restenosis rates, and ﬁve of six were still
patent at 48 months (17% restenosis).18
EVBT. EVBT in peripheral arteries was initially
described in 1994 to prevent restenosis in peripheral ar-
teries.32 Angioplasty and stent implantation cause a
rupture of the internal elastic lamina, leading to migration
of smooth muscle cells from the media into the intima,
which proliferate and produce extracellular matrix. This
results in intimal hyperplasia and subsequent arterial
luminal narrowing.33 Radiation itself can cause cicatri-
zation in the vascular system, but this occurs only after high
doses and is not anticipated to occur at the dose of radia-
tion used for EVBT. At the low doses of radiation used
with EVBT, there is a signiﬁcant reduction of mitosis in the
most exposed cells with only isolated cell necrosis.24 This
effect and the reduction in smooth muscle cell migration
are probably responsible for preventing restenosis.34,35
Brachytherapy was approved by the FDA in November
2000 for coronary artery in-stent restenosis.3 The beta-
emitting strontium source device (90Sr/90Y) has proved
to be the more practical and effective device and is
currently the only available device on the market. Although
it is not yet FDA approved for RAISR, EVBT has proved
feasible with several case reports in the literature.3,11,24-26
In three case reports, each patient developed early RAISR
(2-6 months) after PTRA, but after subsequent treatment
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6 months.24-26 Aqel et al11 described a patient who devel-
oped RAISR at 7 months treated with a second stent,
which restenosed again at 11 months. After treatment
with a third stent and brachytherapy, the renal artery was
still patent at 24 months. There have been larger trials,
all revealing similar restenosis rates.9,10,27 In a Swiss study,
11 patients were treated with EVBT for RAISR and 10
were available for follow-up, with restenosis occurring in
30% at 18 months.9 Jahraus et al10 treated ﬁve patients
with EVBT, and one patient developed restenosis (20%)
at 5 months. In the largest trial, Williams et al27 examined
beta radiation brachytherapy in 15 patients with RAISR.
There were three restenosed stents (20%) at a mean
follow-up of 12 months. In our series, 22 of 23 renal ar-
teries were patent at a mean follow-up of 43.9 months.
Of note is that one patient had undergone two PTRAs
for RAISR before EVBT, both of which resulted in recur-
rent stenosis occurring at 4 and 8 months. After EVBT, the
renal stent remained patent for 42 months. Favorable re-
sults also occurred in the two small stents (4 mm).
We do not have an explanation for the improved results
in our series. In the Swiss trial, restenosis was 70%, but
gamma radiation was used (192Ir), and this may not be
comparable to beta radiation.9 In the largest of the previ-
ous trials, the median dose prescribed was 21 Gy compared
with 18.4 Gy in our series.27 Jahraus et al10 also used a
higher dose of beta radiation of 20.29 Gy. The restenosis
in the one patient of ﬁve total in that study was in a vessel
supplying a renal allograft, which may not be comparable.
Further, variable doses at the luminal surface could result
on the basis of where the catheter is centered, and this
may also explain different outcomes.
The recently published Cardiovascular Outcomes in
Renal Atherosclerotic Lesions (CORAL) trial suggests that
renal artery stenting does not confer a signiﬁcant beneﬁt
in patients with atherosclerotic renal artery stenosis, hyper-
tension, or chronic kidney disease compared with best med-
ical therapy.12 Because the end points to the CORAL study
were clinical and there was no follow-up with renal artery
duplex imaging, it is plausible that some of the renal stent
patients developed unrecognized RAISR, explaining the
lack of improvement with renal artery stenting. Irrespective
of this, we expect a decline in the use of renal stents. How-
ever, there are still many patients with previous renal stents
who are at risk for RAISR, and the question then remains as
to how these patients should be treated. The CORAL study
would suggest that recurrent in-stent restenosis does not
warrant repeated procedures either. However, RAISR may
prove to be even more stenotic than the original lesion.
Also, for patients who fail to respond to medical therapy
or are unable to tolerate medical therapy, stenting or
repeated dilation of the stent remains a reasonable option
(The Society for Cardiovascular Angiography and Interven-
tions statement on CORAL, November 18, 2013; and per-
sonal communication with Christopher J. White, MD, New
Orleans La, 2014). Symptomatic patients with RAISR in a
solitary kidney and patients with ﬂash pulmonary edemaand bilateral renal artery stenosis may also represent a failure
of medical therapy and warrant repeated renal artery stent
dilation. Our data suggest that concurrent EVBT would
be the most viable option because there was a more than
fourfold increase in the average patency compared with
the average patency of the initial RAISR group. The tech-
nique was also safe, with no early or late adverse events.
Limitations. The clinical beneﬁt of brachytherapy in
our patients was limited to a reduction in systolic blood pres-
sure despite the need for continued antihypertensives. Beta
radiation has been shown to result in perierenal artery sym-
pathetic denervation in animals, so it is possible that some of
the blood pressure lowering seen in this small seriesmay have
resulted from such an effect rather than from restoration of
stent patency.36 Accordingly, the implication of our re-
ported results is not that brachytherapy should necessarily be
considered as providing clinical beneﬁt, but rather, if indi-
cated, it will usually be successful in preventing or delaying
restenosis. Our study has limitations because of its retro-
spective design, which should be considered in interpreting
the results. A prospective, randomized controlled trial would
be preferable for investigating the safety and efﬁcacy of
EVBT for RAISR, and it is clearly needed. However, we
believe that our clinical series has contributed to a better
understanding of the value of EVBT for RAISR.
CONCLUSIONS
This retrospective experience with a relatively small
number of patients undergoing concurrent EVBT/PTRA
for recurrent stenosis in stents placed to treat atheroscle-
rotic renal artery stenosis suggests that EVBT is safe and
provides long-term freedom from recurrent stenosis.
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